

# CARDIABET CRITICARE

S.No	PRODUCT NAME	COMPOSITION	PACKING
<b>CARDIAC RANGE</b>			
1	<b>ATOLVA-10</b>	<b>Atorvastatin 10 mg</b> 1. Reduces the risk of myocardial infarction. 2. Atorvastatin is an oral drug that lowers the level of cholesterol in the blood. 3. Atorvastatin also reduces the concentration of triglycerides in the blood.	ALU-ALU
2	<b>ATOLVA-20</b>	<b>Atorvastatin 20 mg</b> 1. Reduces the risk of myocardial infarction. 2. Atorvastatin is an oral drug that lowers the level of cholesterol in the blood. 3. Atorvastatin also reduces the concentration of triglycerides in the blood.	ALU-ALU
3	<b>ATOLVA-C10</b>	<b>Atorvastatin 10 mg + Clopidogrel 75 mg</b> 1. Effectively lowers plasma cholesterol & lipoprotein levels. 2. To prevent heart attacks & strokes in persons with heart disease (recent heart attack), recent stroke, or blood circulation disease (peripheral vascular disease).	ALU-ALU
4	<b>ATOLVA-F</b>	<b>Atorvastatin 10mg + Fenofibrate 160mg</b> 1. Atorvastatin is used along with a proper diet to help lower "bad" cholesterol and fats (such as LDL, triglycerides) and raise "good" cholesterol (HDL) in the blood. 2. Fenofibrate helps reduce cholesterol and triglycerides (fatty acids) in the blood. 3. High levels of these types of fat in the blood are associated with an increased risk of atherosclerosis (clogged arteries).	10x10 TAB.
5	<b>AMTOPROL-AL</b>	<b>Metoprolol 50mg XL + Amlodipine 5mg</b> 1. well documented efficacy in angina pectoris reducing the frequency, duration & severity of angina attacks. 2. A selective calcium channel blocker vaso dilator. 3. Reduces total peripheral resistance.	BLISTER
6	<b>CALROV-10</b>	<b>Rosuvastatin Calcium 10mg</b> 1. 54% relative risk reduction in myocardial infarction. 2. 48% relative risk reduction in stroke. 3. 47% relative risk reduction in revascularization procedures.	ALU-ALU
7	<b>CALROV-20</b>	<b>Rosuvastatin Calcium 20mg</b>	ALU-ALU
8	<b>CALROV-F</b>	<b>Rosuvastatin 10mg + Fenofibrate 160mg</b>	ALU-ALU
9	<b>TELISKA-40</b>	<b>Telmisartan HCL 40mg</b> 1. Protective benefits against the vascular and renal damage caused by diabetes and cardiovascular disease. 2. Blocks angiotensin receptor.	ALU-ALU

10	TELISKA-H	<b>Telmisartan HCL 40mg + Hydrochlorothiazide 12.5mg</b> 1. Reduces arterial blood pressure. 2. Low dose thiazide diuretics are associated with an additional reduction in CHD & total mortality.	ALU-ALU
11	TELSIKA-AM	<b>Telmisartan 40mg + Amlodipine 5mg</b> 1. More effective than Losartan in controlling SBP. 2. Offers highest PPAR Gamma activation as compared to any other ARB.	ALU-ALU
12	TELISKA-AM-H	<b>Amlodipine 5mg + Telmisartan HCL 40mg + Hydrochlorothiazide 12.5mg</b> 1. Reduces arterial blood pressure. 2. Low dose thiazide diuretics are associated with an additional reduction in CHD & total mortality. 3. More effective than Losartan in controlling SBP. 4. Offers highest PPAR Gamma activation as compared to any other ARB.	BLISTER
13	TELISKA-CL	<b>Telmisartan 40mg+Clindipine 10mg</b>	ALU-ALU
14	TELISKA-CH 6.25	<b>Telmisartan 40 + Chlorthalidone 6.25</b>	ALU-ALU
<b>DAIBETIC RANGE</b>			
15	GLISPO-1M	<b>Glimepride 1mg + Metformin 500mg (SR)</b> 1. Highly effective in patients having both high fasting and high post-prandial blood glucose levels. 2. The addition of glimepride to MET is an effective treatment for patients inadequately controlled on sulfonylurea or Met alone.	BLISTER (BI-LAYERED)
16	GLISPO-2M	<b>Glimepride 2mg + Metformin 500mg (SR)</b> After the intensive treatment, FPG, 2 HPG & HBA1c decreased significantly (p<0.01); HOMA-IR decreased & HOMA-B increased significantly (p<0.01) & TG, CHOL, LDL decreased significantly (p<0.01) after treatment	BLISTER (BI-LAYERED)
17	GLISPO-2M FORTE	<b>Glimepride 2mg + Metformin 1000mg SR (SR)</b> After the intensive treatment, FPG, 2 HPG & HBA1c decreased significantly (p<0.01); HOMA-IR decreased & HOMA-B increased significantly (p<0.01) & TG, CHOL, LDL decreased significantly (p<0.01) after treatment	BLISTER (BI-LAYERED)
18	GLISPO-PM1/15	<b>Glimepride 1mg + Metformin 500mg (SR) + Pioglitazone 15 mg</b> 1. Stimulates the release of insulin from functioning pancreatic beta cells. 2. Counters insulin resistance. 3. decreases hepatic glucose production also decreases intestinal absorption of glucose.	BLISTER (BI-LAYERED)

19	<b>GLISPO-PM2/15</b>	<b>Glimepride 2mg + Metformin 500mg (SR) + Pioglitazone 15 mg</b> 1. Stimulates the release of insulin from functioning pancreatic beta cells. 2. Counters insulin resistance. 3. decreases hepatic glucose production also decreases intestinal absorption of glucose.	BLISTER (BI-LAYERED)
20	<b>TRIBOG-1.2</b>	<b>Glimepride 1mg + Voglibose 0.2mg + Metformin 500mg (SR)</b> 1. Voglibose scores over both acarbose and miglitol in terms of side effect profile. 2. proven efficacy. 3. metformin causes few adverse effects the most common is gastrointestinal upset and is associated with a low risk of hypoglycemia.	BLISTER (BI-LAYERED)
21	<b>TRIBOG-2.2</b>	<b>Glimepride 2mg + Voglibose 0.2mg + Metformin 500mg (SR)</b> 1. Voglibose scores over both acarbose and miglitol in terms of side effect profile. 2. proven efficacy. 3. metformin causes few adverse effects the most common is gastrointestinal upset and is associated with a low risk of hypoglycemia.	BLISTER (BI-LAYERED)
22	<b>GLYCLIP-20</b>	<b>Teneligliptin 20 mg</b> Teneligliptin is used in the treatment of type 2 diabetes It is used in addition to diet and exercise to improve blood sugar control in adults with type 2 diabetes.	ALU-ALU
23	<b>LORIPTA-V</b>	<b>Vidagliptin 50mg</b> It helps to control the levels of sugar (glucose) in your blood. If your body does not make enough insulin, or if it does not use the insulin it makes effectively, this results in the condition called sugar diabetes	ALU-ALU
24	<b>LORIPTA-VM</b>	<b>Vidagliptin 50mg + Metformin 500 mg</b> It is used to treat type 2 diabetes mellitus in people who are already taking vildagliptin and metformin tablets separately, or whose diabetes cannot be controlled by metformin alone Type 2 diabetes mellitus used to be known as 'non-insulin-dependent diabetes mellitus (NIDDM)' or 'maturity onset diabetes	BLISTER (BI-LAYERED)
25	<b>VOBTRI-0.3MD</b>	<b>Voglibose 0.3mg (MD)</b> Voglibose inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.	ALU-ALU

### **TERMS AND CONDITIONS**

1	WE STRICTLY DEAL ON CASH BASIS ONLY.
2	We need xerox (Photocopy) of sale tax number i.e G.S.T. and D.L. number.
3	The prices are exclusive of G.S.T.
4	Invoice will be raised only after the receipt of advance payment.
5	No Expiry and Breakage will be entertained.
6	The prices may change without prior notice.
7	Promotional material can be given for free (in limited qty.) as per demand like: LBL's, Catch covers, Reminder cards
8	All dispute subject to PANCHKULA jurisdiction only.
9	F.O.R. TO BE PAID BY PARTY.

10	All prices are ex PANCHKULA
11	Payment should be made by DD/At par cheque in favour of VISHAM LIFECARE payable at PANCHKULA.
<b>CONTACT DETAILS</b>	
<b>FOR ACCOUNTS :-</b>	
1	Mr. ZIYAU HAQUE : 92165-59100
<b>FOR MARKETING :-</b>	
2	Mr. ANIL: 9517908391
<b>FOR ANY QUERY &amp; COMPLAINTS :-</b>	
MR. VISHAL JASUJA (DIRECTOR) : 92165-57100	